2025-521828-30-00招募中2 期
Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 9
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Trial Manager
Scientific
Pyxis Oncology Inc.
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase 2 Study of MRTX849 Plus Pembrolizumab in Patients with AdvancedNon-Small Cell Lung Cancer with KRAS G12C MutatioAdvanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003101-58-ITMIRATI THERAPEUTICS INCORPORATED120
已完成
2 期
Phase II study of pemetrexed or pemetrexed plus bevacizumab for previously untreated elderly non-squamous non-small cell lung cancerJPRN-UMIN000008771ung Oncology Group in Kyushu, Japan (LOGIK)82
已完成
1 期
A Phase 1b Study of LY2157299 in Combination with Sorafenib in Patients with Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaJPRN-jRCT2080222658Eli Lilly Japan K.K.
已完成
1 期
A Phase 1b Study of LY2157299 in Combination with Sorafenib in Patients with Unresectable Hepatocellular CarcinomaHepatocellular CarcinomajRCT2080222658Eli Lilly Japan K.K.
未知
1 期
A Phase 1b Study of LY2157299 in Combination With Gemcitabine in Patients With Advanced or Metastatic Unresectable Pancreatic Cancer (H9H-JE-JBAO)jRCT2080222513Eli Lilly Japan K.K.